SpaceX is raising $75 billion at a $1.75 trillion valuation, targeting an IPO date of June 12, making it the largest IPO in history.
SpaceX's $2T IPO, Karpathy Joins Anthropic & the SaaSpocalypse — ft. Dr Dan | EP14
Cursor's $3B revenue run rate may actually cost them $6B to deliver — and Dr. Dan thinks every B2B SaaS database-with-an-interface is now a one-click clone.
May 22, 2026
1:06:54
Difficulty: Intermediate
Played
God Mode Podcast
SpaceX's $2T IPO, Karpathy Joins Anthropic & the SaaSpocalypse — ft. Dr Dan | EP14
Cursor's $3B revenue run rate may actually cost them $6B to deliver — and Dr. Dan thinks every B2B SaaS database-with-an-interface is now a one-click clone.
May 22, 2026
1:06:54
Difficulty: Intermediate
Played
Chapter
No indexed bits in this chapter.
Snapshots ()
Stats
Episode stats
Insight Overview
insights
chapters
Insight distribution
Sub-Categories
Speaker breakdown
Talk Time
Key Quotes ()
This episode
Cast
-
Described as a master of hype; behind SpaceX's IPO, the Cursor acquisition deal, and providing compute to Anthropic.
-
OpenAI founding member who joined Anthropic for R&D; seen as the single most bullish signal for Anthropic's credibility.
-
Tech entrepreneur whose 'network state' concept inspired Network School, where Dr. Dan is currently living.
-
Offering $2M in credits to each YC startup; targeting an IPO in September; developing Codex as its agentic coding tool.
-
Filed the largest IPO in history at a $1.75T valuation; reportedly planning to acquire Cursor and provide compute to Anthropic.
-
AI lab reaching profitability; Andrej Karpathy joined for R&D; Dr. Dan calls it mostly hype and marketing but says Karpathy's hire is bullish.
-
Balaji Srinivasan's co-living and learning community near Singapore in Malaysia, where Dr. Dan is currently based.
-
Startup accelerator whose current batch of ~200 companies is being offered $2M in OpenAI credits each.
-
Conducting AI-first restructuring layoffs; employees received termination emails at 4AM after being told to work from home.
-
Canceled its internal Claude Code licenses after token-based billing became too expensive; cited as an example of SaaS cost pressure.
-
Chinese electric vehicle company that buys automated factory equipment from an unnamed Shenzhen manufacturer Dr. Dan visited.
-
Pharmaceutical company developing an oral semaglutide pill formulation as a future alternative to injections.
-
Taiwan Semiconductor Manufacturing Company; Ben cited speculation that Elon Musk would poach TSMC engineers to build a chip facility in Texas.
-
AI coding IDE reportedly being acquired by SpaceX for $60B; Dr. Dan argues it has no real moat and fine-tunes Chinese models.
-
OpenAI's agentic coding tool; Dr. Dan's preferred tool, claiming it delivers 7-8x more value than Claude Code per dollar.
-
Anthropic's agentic coding tool; Dr. Dan prefers Codex overall but acknowledges Claude Code is better at debugging multi-agent tasks.
-
GLP-1 weight-loss drug (semaglutide) that unlocked the mass market for obesity treatment; costs ~$400/month in the US vs $10-20 from China.
-
Third-generation triple GLP-1/GIP/glucagon agonist showing 28.3% body weight loss in Phase 3 trials over 80 weeks.
This episode
Claims & Sources
2 / 15 cited (13%)
Factual claims made this episode, and whether a source was named.
Cursor fine-tunes Chinese models rather than building its own frontier AI models.
Claude Code forcibly adds itself as a collaborator on GitHub commits even when explicitly told not to.
OpenAI's $2 million credits to each YC startup in the current batch amounts to roughly $400 million in total tokens given away across ~200 companies.
AI lab coding subscriptions are deliberately priced below cost as loss leaders to gain market share, while API pricing carries actual margins.
Microsoft canceled its internal Claude Code licenses after token-based billing made the cost untenable.
Taking a drug from early research to market approval costs an average of $2.3 billion and takes a median of 15 years.
Retatrutide Phase 3 trials showed 28.3% body weight loss on 12mg over 80 weeks.
Natural GLP-1 has a half-life of approximately 30 minutes in the blood.
Ozempic (semaglutide) requires only one injection per week versus two injections per day for its predecessor liraglutide, while delivering double the therapeutic effect.
Less than 1% of therapeutic findings proven in mouse studies successfully transfer to humans.
Cursor is at a $3 billion annual revenue run rate ahead of the SpaceX acquisition deal.
Anthropic has raised approximately $60–80 billion to date, while OpenAI's last funding round alone was $100 billion.
Codex ran autonomously for 7 hours and 25 minutes to build and fully test an ERP system based on a detailed plan document.
SpaceX is reportedly planning to acquire Cursor approximately 30 days after its IPO for $60 billion, with a $10 billion walk-away penalty.
TL;DR
Three tech enthusiasts — host Rik, co-host Ben, and guest Dr. Dan (ex-Google, now a vibe coder at Network School near Singapore) — dissect the week's biggest AI and tech stories. SpaceX's $1.75T IPO leads the conversation, followed by Andrej Karpathy's surprise move to Anthropic, the brutal Cursor vs. Codex vs. Claude Code debate, and why B2B SaaS margins are collapsing. The episode closes with a surprisingly deep breakdown of GLP-1 peptides, Ozempic, and retatrutide. Key takeaway: in the AI era, distribution and proprietary data are the only real moats left.
#SpaceX IPO
#AI coding tools
#Cursor vs Codex
#Claude Code
#SaaS disruption
#GLP-1 peptides
#Ozempic alternatives
#retatrutide Phase 3
#Andrej Karpathy Anthropic
#vibe coding
#B2B SaaS margins
#AI agents
#pharma compounding loophole
#Shenzhen manufacturing
#solopreneur economy
#Andrej Karpathy
#Anthropic
#OpenAI
#Cursor
#Codex
#SaaSPocalypse
#GLP-1
#Ozempic
#retatrutide
#AI coding
#B2B SaaS
#peptides
#weight loss
#Elon Musk
#Shenzhen
#Network School
2 minute taster
The SaaSPocalypse: Every B2B Database-With-an-Interface Is a One-Click Clone
B2B SaaS built on a glorified database is now a one-click clone. The industries with real staying power are those with physical assets, proprietary distribution, or deeply entrenched systems of record. Every other SaaS product will be commoditized like a cheap IKEA chair.
Codex Built an Entire ERP System Overnight — Without Human Input
Dan gave Codex a detailed plan for a full ERP system and went to sleep. Seven hours and 25 minutes later, it was done — end-to-end tested, click-through verified. Claude Code can't do this. We are entering the era of fast fashion software.
Look closer
SpaceX filed the biggest IPO in history at a $1.75T valuation. Andrej Karpathy left OpenAI for Anthropic. The AI coding wars heated up with Cursor vs Codex vs Claude Code debates. Plus a full breakdown of GLP-1 peptides, Ozempic, and retatrutide.
Chapter list
- GLP-1
- Glucagon-like peptide-1, a messenger molecule produced in the gut that signals fullness to the brain and moderates insulin sensitivity; the target receptor for Ozempic and related weight-loss drugs.
- Tirzepatide
- A dual GLP-1/GIP receptor agonist sold as Mounjaro/Zepbound; the second-generation obesity drug after semaglutide (Ozempic), offering stronger weight-loss effects.
- Retatrutide
- A triple agonist targeting GLP-1, GIP, and glucagon receptors; the third-generation obesity drug showing ~28% body-weight loss in Phase 3 trials.
- Semaglutide
- The active ingredient in Ozempic/Wegovy; a GLP-1 receptor agonist engineered to have a long half-life so it only needs weekly injection.
- GIP
- Glucose-dependent insulinotropic polypeptide, a gastrointestinal hormone that works alongside GLP-1 to regulate insulin; targeted by tirzepatide and retatrutide.
- Compounding pharmacy
- A US pharmacy legally permitted to prepare custom drug formulations for individual patients; exploited as a loophole to sell cheaper, unbranded versions of Ozempic.
- Loss leader
- A product sold below cost to attract customers, with the intent of making profit on future purchases; described here as the pricing strategy for AI coding subscriptions.
- Moat
- A durable competitive advantage that protects a business from rivals; used repeatedly to assess whether Cursor, Anthropic, and SpaceX have defensible positions.
- SaaSPocalypse
- Coined term for the predicted collapse of B2B SaaS margins as AI enables businesses to clone or self-build software instead of purchasing subscriptions.
- Vibe coding
- AI-assisted software development where a user describes desired functionality in natural language and lets an AI agent generate and iterate on the code with minimal manual coding.
- Agentic
- Describes AI systems that autonomously plan and execute multi-step tasks without continuous human input; Meta and others are restructuring teams around agentic AI.
- Responses API
- OpenAI's stateful API that retains conversation history server-side so callers only need to send new turns, used as a lock-in mechanism.
- Prompt caching
- A technique where repeated portions of a prompt (e.g., system instructions) are stored and reused to reduce token processing costs on subsequent API calls.
- BPC-157
- Body Protection Compound 157, a synthetic peptide claimed to accelerate tissue repair; popular in biohacking circles but largely studied only in animal models.
- TB-500
- Thymosin Beta-4 fragment, a synthetic peptide used alongside BPC-157 for purported tissue regeneration; limited peer-reviewed human evidence.
- Half-life
- The time it takes for a substance's concentration in the blood to fall by half; natural GLP-1 has a half-life of about 30 minutes, driving the engineering of longer-lasting analogs.
- CapEx
- Capital expenditure — large upfront investment in physical assets; used here to describe the $2.3B average cost of bringing a drug to market.
- Solopreneur
- A solo entrepreneur who runs a business independently without employees, leveraging tools like AI to replace traditional team functions.
- Bioavailability
- The proportion of a drug that enters circulation and reaches its site of action; oral ingestion of peptides has lower bioavailability than direct injection.
- Gut motility
- The speed at which food moves through the digestive tract; GLP-1 agonists slow gut motility, contributing to feelings of fullness and reduced appetite.
